-
1
-
-
0141865697
-
How the field of thyroid endocrinology developed in france after World War II
-
2-s2.0-0141865697
-
Fragu P., How the field of thyroid endocrinology developed in france after World War II. Bulletin of the History of Medicine 2003 77 2 393 414 10.1353/bhm.2003.0063 2-s2.0-0141865697
-
(2003)
Bulletin of the History of Medicine
, vol.77
, Issue.2
, pp. 393-414
-
-
Fragu, P.1
-
2
-
-
84958695064
-
The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies
-
Pressman D., Korngold L., The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953 6 3 619 623
-
(1953)
Cancer
, vol.6
, Issue.3
, pp. 619-623
-
-
Pressman, D.1
Korngold, L.2
-
4
-
-
0025068419
-
Chelates and antibodies: Current methods and new directions
-
2-s2.0-0025068419
-
Gansow O. A., Brechbiel M. W., Mirzadeh S., Colcher D., Roselli M., Chelates and antibodies: current methods and new directions. Cancer Treatment and Research 1990 51 153 171 10.1007/978-1-4613-1497-4-7 2-s2.0-0025068419
-
(1990)
Cancer Treatment and Research
, vol.51
, pp. 153-171
-
-
Gansow, O.A.1
Brechbiel, M.W.2
Mirzadeh, S.3
Colcher, D.4
Roselli, M.5
-
5
-
-
0025115329
-
Stable bifunctional chelates of metals used in radiotherapy
-
2-s2.0-0025115329
-
Moi M. K., DeNardo S. J., Meares C. F., Stable bifunctional chelates of metals used in radiotherapy. Cancer Research 1990 50 3 S789 S793 2-s2.0-0025115329
-
(1990)
Cancer Research
, vol.50
, Issue.3
, pp. S789-S793
-
-
Moi, M.K.1
Denardo, S.J.2
Meares, C.F.3
-
7
-
-
64649084383
-
Radiation-induced bystander signalling in cancer therapy
-
2-s2.0-64649084383
-
Prise K. M., O'Sullivan J. M., Radiation-induced bystander signalling in cancer therapy. Nature Reviews Cancer 2009 9 5 351 360 10.1038/nrc2603 2-s2.0-64649084383
-
(2009)
Nature Reviews Cancer
, vol.9
, Issue.5
, pp. 351-360
-
-
Prise, K.M.1
O'Sullivan, J.M.2
-
9
-
-
34547121206
-
Hypoxia in cancer: Significance and impact on clinical outcome
-
2-s2.0-34547121206
-
Vaupel P., Mayer A., Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews 2007 26 2 225 239 10.1007/s10555-007-9055-1 2-s2.0-34547121206
-
(2007)
Cancer and Metastasis Reviews
, vol.26
, Issue.2
, pp. 225-239
-
-
Vaupel, P.1
Mayer, A.2
-
10
-
-
33845977959
-
Mitochondrial membrane permeabilization in cell death
-
2-s2.0-33845977959
-
Kroemer G., Galluzzi L., Brenner C., Mitochondrial membrane permeabilization in cell death. Physiological Reviews 2007 87 1 99 163 10.1152/physrev.00013.2006 2-s2.0-33845977959
-
(2007)
Physiological Reviews
, vol.87
, Issue.1
, pp. 99-163
-
-
Kroemer, G.1
Galluzzi, L.2
Brenner, C.3
-
11
-
-
84855714255
-
BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation
-
2-s2.0-84855714255
-
Cabon L., Galán-Malo P., Bouharrour A., Delavallée L., Brunelle-Navas M.-., Lorenzo H. K., Gross A., Susin S. A., BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. Cell Death and Differentiation 2012 19 2 245 256 10.1038/cdd.2011.91 2-s2.0-84855714255
-
(2012)
Cell Death and Differentiation
, vol.19
, Issue.2
, pp. 245-256
-
-
Cabon, L.1
Galán-Malo, P.2
Bouharrour, A.3
Delavallée, L.4
Lorenzo, H.K.5
Gross, A.6
Susin, S.A.7
-
12
-
-
0036494443
-
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
-
2-s2.0-0036494443
-
Ganss R., Ryschich E., Klar E., Arnold B., Hämmerling G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Research 2002 62 5 1462 1470 2-s2.0-0036494443
-
(2002)
Cancer Research
, vol.62
, Issue.5
, pp. 1462-1470
-
-
Ganss, R.1
Ryschich, E.2
Klar, E.3
Arnold, B.4
Hämmerling, G.J.5
-
13
-
-
79952281184
-
Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
-
2-s2.0-79952281184
-
Tartour E., Pere H., Maillere B., Terme M., Merillon N., Taieb J., Sandoval F., Quintin-Colonna F., Lacerda K., Karadimou A., Badoual C., Tedgui A., Fridman W. H., Oudard S., Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews 2011 30 1 83 95 10.1007/s10555-011-9281-4 2-s2.0-79952281184
-
(2011)
Cancer and Metastasis Reviews
, vol.30
, Issue.1
, pp. 83-95
-
-
Tartour, E.1
Pere, H.2
Maillere, B.3
Terme, M.4
Merillon, N.5
Taieb, J.6
Sandoval, F.7
Quintin-Colonna, F.8
Lacerda, K.9
Karadimou, A.10
Badoual, C.11
Tedgui, A.12
Fridman, W.H.13
Oudard, S.14
-
14
-
-
57349122162
-
Auger processes in the 21st century
-
2-s2.0-57349122162
-
Howell R. W., Auger processes in the 21st century. International Journal of Radiation Biology 2008 84 12 959 975 10.1080/09553000802395527 2-s2.0-57349122162
-
(2008)
International Journal of Radiation Biology
, vol.84
, Issue.12
, pp. 959-975
-
-
Howell, R.W.1
-
15
-
-
0037083401
-
Radionuclide-antibody conjugates for single-cell cytotoxicity
-
2-s2.0-0037083401
-
Mattes M. J., Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 2002 94 4 1215 1223 10.1002/cncr.10288 2-s2.0-0037083401
-
(2002)
Cancer
, vol.94
, Issue.4
, pp. 1215-1223
-
-
Mattes, M.J.1
-
16
-
-
0035136997
-
Single-cell cytotoxicity with radiolabeled antibodies
-
2-s2.0-0035136997
-
Ong G. L., Elsamra S. E., Goldenberg D. M., Jules Mattes M., Single-cell cytotoxicity with radiolabeled antibodies. Clinical Cancer Research 2001 7 1 192 201 2-s2.0-0035136997
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.1
, pp. 192-201
-
-
Ong, G.L.1
Elsamra, S.E.2
Goldenberg, D.M.3
Jules Mattes, M.4
-
19
-
-
0031715792
-
Radioimmunotherapy with α-emitting nuclides
-
2-s2.0-0031715792
-
McDevitt M. R., Sgouros G., Finn R. D., Humm J. L., Jurcic J. G., Larson S. M., Scheinberg D. A., Radioimmunotherapy with α-emitting nuclides. European Journal of Nuclear Medicine 1998 25 9 1341 1351 10.1007/s002590050306 2-s2.0-0031715792
-
(1998)
European Journal of Nuclear Medicine
, vol.25
, Issue.9
, pp. 1341-1351
-
-
McDevitt, M.R.1
Sgouros, G.2
Finn, R.D.3
Humm, J.L.4
Jurcic, J.G.5
Larson, S.M.6
Scheinberg, D.A.7
-
20
-
-
84887362097
-
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma
-
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. The Journal of Nuclear Medicine 2013 54 9 1597 1604
-
(2013)
The Journal of Nuclear Medicine
, vol.54
, Issue.9
, pp. 1597-1604
-
-
Chérel, M.1
Gouard, S.2
Gaschet, J.3
-
21
-
-
67651168088
-
Astatine radiopharmaceuticals: Prospects and problems
-
Vaidyanathan G., Zalutsky M. R., Astatine radiopharmaceuticals: prospects and problems. Current Radiopharmaceuticals 2008 1 3 177 196 10.2174/1874471010801030177
-
(2008)
Current Radiopharmaceuticals
, vol.1
, Issue.3
, pp. 177-196
-
-
Vaidyanathan, G.1
Zalutsky, M.R.2
-
22
-
-
46949107981
-
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications
-
2-s2.0-46949107981
-
Miederer M., Scheinberg D. A., McDevitt M. R., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews 2008 60 12 1371 1382 10.1016/j.addr.2008.04.009 2-s2.0-46949107981
-
(2008)
Advanced Drug Delivery Reviews
, vol.60
, Issue.12
, pp. 1371-1382
-
-
Miederer, M.1
Scheinberg, D.A.2
McDevitt, M.R.3
-
24
-
-
77955645834
-
Design and development of molecular imaging probes
-
2-s2.0-77955645834
-
Chen K., Chen X., Design and development of molecular imaging probes. Current Topics in Medicinal Chemistry 2010 10 12 1227 1236 10.2174/156802610791384225 2-s2.0-77955645834
-
(2010)
Current Topics in Medicinal Chemistry
, vol.10
, Issue.12
, pp. 1227-1236
-
-
Chen, K.1
Chen, X.2
-
25
-
-
78649325858
-
Target-specific delivery of peptide-based probes for PET imaging
-
2-s2.0-78649325858
-
Chen K., Conti P. S., Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews 2010 62 11 1005 1022 10.1016/j.addr.2010.09.004 2-s2.0-78649325858
-
(2010)
Advanced Drug Delivery Reviews
, vol.62
, Issue.11
, pp. 1005-1022
-
-
Chen, K.1
Conti, P.S.2
-
26
-
-
0016756272
-
Continuous cultures of fused cells secreting antibody of predefined specificity
-
2-s2.0-0016756272
-
Köhler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 5517 495 497 10.1038/256495a0 2-s2.0-0016756272
-
(1975)
Nature
, vol.256
, Issue.5517
, pp. 495-497
-
-
Köhler, G.1
Milstein, C.2
-
27
-
-
0023156998
-
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018
-
2-s2.0-0023156998
-
Murray J. L., Rosenblum M. G., Lamki L., Glenn H. J., Krizan Z., Hersh E. M., Plager C. E., Bartholomew R. M., Unger M. W., Carlo D. J., Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018. The Journal of Nuclear Medicine 1987 28 1 25 33 2-s2.0-0023156998
-
(1987)
The Journal of Nuclear Medicine
, vol.28
, Issue.1
, pp. 25-33
-
-
Murray, J.L.1
Rosenblum, M.G.2
Lamki, L.3
Glenn, H.J.4
Krizan, Z.5
Hersh, E.M.6
Plager, C.E.7
Bartholomew, R.M.8
Unger, M.W.9
Carlo, D.J.10
-
28
-
-
0023885888
-
2 and Fab fragments
-
2-s2.0-0023885888
-
2 and Fab fragments. The Journal of Nuclear Medicine 1988 29 7 1212 1222 2-s2.0-0023885888
-
(1988)
The Journal of Nuclear Medicine
, vol.29
, Issue.7
, pp. 1212-1222
-
-
Rosebrough, S.F.1
Grossman, Z.D.2
McAfee, J.G.3
Kudryk, B.J.4
Subramanian, G.5
Ritter-Hrncirik, C.A.6
Witanowski, L.S.7
Tillapaugh-Fay, G.8
Urrutia, E.9
Zapf-Longo, C.10
-
29
-
-
27144550160
-
Arming antibodies: Prospects and challenges for immunoconjugates
-
2-s2.0-27144550160
-
Wu A. M., Senter P. D., Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 2005 23 9 1137 1146 10.1038/nbt1141 2-s2.0-27144550160
-
(2005)
Nature Biotechnology
, vol.23
, Issue.9
, pp. 1137-1146
-
-
Wu, A.M.1
Senter, P.D.2
-
30
-
-
84889848914
-
Future prospects of monoclonal antibodies as magic bullets in immunotherapy
-
Maleki L. A., Baradaran B., Majidi J., Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Human Antibodies 2013 22 1-2 9 13
-
(2013)
Human Antibodies
, vol.22
, Issue.1-2
, pp. 9-13
-
-
Maleki, L.A.1
Baradaran, B.2
Majidi, J.3
-
31
-
-
0037317431
-
131I-anti-B1 antibody: Assessment of tumor dose-response
-
2-s2.0-0037317431
-
131I-anti-B1 antibody: assessment of tumor dose-response. The Journal of Nuclear Medicine 2003 44 2 260 268 2-s2.0-0037317431
-
(2003)
The Journal of Nuclear Medicine
, vol.44
, Issue.2
, pp. 260-268
-
-
Sgouros, G.1
Squeri, S.2
Ballangrud, A.M.3
Kolbert, K.S.4
Teitcher, J.B.5
Panageas, K.S.6
Finn, R.D.7
Divgi, C.R.8
Larson, S.M.9
Zelenetz, A.D.10
-
32
-
-
1342307630
-
90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response?
-
2-s2.0-1342307630
-
90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? The Journal of Nuclear Medicine 2003 44 12 2000 2018 2-s2.0-1342307630
-
(2003)
The Journal of Nuclear Medicine
, vol.44
, Issue.12
, pp. 2000-2018
-
-
Sharkey, R.M.1
Brenner, A.2
Burton, J.3
Hajjar, G.4
Toder, S.P.5
Alavi, A.6
Matthies, A.7
Tsai, D.E.8
Schuster, S.J.9
Stadtmauer, E.A.10
Czuczman, M.S.11
Lamonica, D.12
Kraeber-Bodere, F.13
Mahe, B.14
Chatal, J.15
Rogatko, A.16
Mardirrosian, G.17
Goldenberg, D.M.18
-
33
-
-
74849131675
-
Radioimmunotherapy of lymphoma: Bexxar and zevalin
-
2-s2.0-74849131675
-
Goldsmith S. J., Radioimmunotherapy of lymphoma: bexxar and zevalin. Seminars in Nuclear Medicine 2010 40 2 122 135 10.1053/j.semnuclmed.2009.11.002 2-s2.0-74849131675
-
(2010)
Seminars in Nuclear Medicine
, vol.40
, Issue.2
, pp. 122-135
-
-
Goldsmith, S.J.1
-
34
-
-
12944275472
-
131I-tositumomab therapy as initial treatment for follicular lymphoma
-
2-s2.0-12944275472
-
131I-tositumomab therapy as initial treatment for follicular lymphoma. The New England Journal of Medicine 2005 352 5 441 449 10.1056/NEJMoa041511 2-s2.0-12944275472
-
(2005)
The New England Journal of Medicine
, vol.352
, Issue.5
, pp. 441-449
-
-
Kaminski, M.S.1
Tuck, M.2
Estes, J.3
Kolstad, A.4
Ross, C.W.5
Zasadny, K.6
Regan, D.7
Kison, P.8
Fisher, S.9
Kroll, S.10
Wahl, R.L.11
-
35
-
-
78650991430
-
131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
-
2-s2.0-78650991430
-
131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 2011 117 1 45 52 10.1182/blood-2010-02-269753 2-s2.0-78650991430
-
(2011)
Blood
, vol.117
, Issue.1
, pp. 45-52
-
-
Leahy, M.F.1
Turner, J.H.2
-
36
-
-
0041761322
-
131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital
-
2-s2.0-0041761322
-
131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biotherapy & Radiopharmaceuticals 2003 18 4 513 524 10.1089/108497803322287583 2-s2.0-0041761322
-
(2003)
Cancer Biotherapy & Radiopharmaceuticals
, vol.18
, Issue.4
, pp. 513-524
-
-
Turner, J.H.1
Martindale, A.A.2
Boucek, J.3
Claringbold, P.G.4
Leahy, M.F.5
-
37
-
-
61849136656
-
131I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
-
2-s2.0-61849136656
-
131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009 113 7 1412 1421 10.1182/blood-2008-08-175653 2-s2.0-61849136656
-
(2009)
Blood
, vol.113
, Issue.7
, pp. 1412-1421
-
-
Illidge, T.M.1
Bayne, M.2
Brown, N.S.3
Chilton, S.4
Cragg, M.S.5
Glennie, M.J.6
Du, Y.7
Lewington, V.8
Smart, J.9
Thom, J.10
Zivanovic, M.11
Johnson, P.W.M.12
-
38
-
-
77957272703
-
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma
-
2-s2.0-77957272703
-
Morschhauser F., Kraeber-Bodéré F., Wegener W. A., Harousseau J., Petillon M., Huglo D., Trümper L. H., Meller J., Pfreundschuh M., Kirsch C., Naumann R., Kropp J., Horne H., Teoh N., Le Gouill S., Bodet-Milin C., Chatal J., Goldenberg D. M., High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. Journal of Clinical Oncology 2010 28 23 3709 3716 10.1200/JCO.2009.27.7863 2-s2.0-77957272703
-
(2010)
Journal of Clinical Oncology
, vol.28
, Issue.23
, pp. 3709-3716
-
-
Morschhauser, F.1
Kraeber-Bodéré, F.2
Wegener, W.A.3
Harousseau, J.4
Petillon, M.5
Huglo, D.6
Trümper, L.H.7
Meller, J.8
Pfreundschuh, M.9
Kirsch, C.10
Naumann, R.11
Kropp, J.12
Horne, H.13
Teoh, N.14
Le Gouill, S.15
Bodet-Milin, C.16
Chatal, J.17
Goldenberg, D.M.18
-
40
-
-
0032694040
-
213Bi-HuM195 (anti-CD33) in patients with leukemia
-
2-s2.0-0032694040
-
213Bi-HuM195 (anti-CD33) in patients with leukemia. The Journal of Nuclear Medicine 1999 40 11 1935 1946 2-s2.0-0032694040
-
(1999)
The Journal of Nuclear Medicine
, vol.40
, Issue.11
, pp. 1935-1946
-
-
Sgouros, G.1
Ballangrud Å., M.2
Jurcic, J.G.3
McDevitt, M.R.4
Humm, J.L.5
Erdi, Y.E.6
Mehta, B.M.7
Finn, R.D.8
Larson, S.M.9
Scheinberg, D.A.10
-
41
-
-
0037103293
-
Targeted α particle immunotherapy for myeloid leukemia
-
2-s2.0-0037103293
-
Jurcic J. G., Larson S. M., Sgouros G., McDevitt M. R., Finn R. D., Divgi C. R., Ballangrud Å. M., Hamacher K. A., Ma D., Humm J. L., Brechbiel M. W., Molinet R., Scheinberg D. A., Targeted α particle immunotherapy for myeloid leukemia. Blood 2002 100 4 1233 1239 2-s2.0-0037103293
-
(2002)
Blood
, vol.100
, Issue.4
, pp. 1233-1239
-
-
Jurcic, J.G.1
Larson, S.M.2
Sgouros, G.3
McDevitt, M.R.4
Finn, R.D.5
Divgi, C.R.6
Ballangrud Å., M.7
Hamacher, K.A.8
Ma, D.9
Humm, J.L.10
Brechbiel, M.W.11
Molinet, R.12
Scheinberg, D.A.13
-
42
-
-
0038315411
-
A comparison of 4 radionuclides conjugated to antibodies for single-cell kill
-
2-s2.0-0038315411
-
Michel R. B., Brechbiel M. W., Mattes M. J., A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. The Journal of Nuclear Medicine 2003 44 4 632 640 2-s2.0-0038315411
-
(2003)
The Journal of Nuclear Medicine
, vol.44
, Issue.4
, pp. 632-640
-
-
Michel, R.B.1
Brechbiel, M.W.2
Mattes, M.J.3
-
43
-
-
8944248819
-
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
-
2-s2.0-8944248819
-
Kaminski M. S., Zasadny K. R., Francis I. R., Fenner M. C., Ross C. W., Milik A. W., Estes J., Tuck M., Regan D., Fisher S., Glenn S. D., Wahl R. L., Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology 1996 14 7 1974 1981 2-s2.0-8944248819
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.7
, pp. 1974-1981
-
-
Kaminski, M.S.1
Zasadny, K.R.2
Francis, I.R.3
Fenner, M.C.4
Ross, C.W.5
Milik, A.W.6
Estes, J.7
Tuck, M.8
Regan, D.9
Fisher, S.10
Glenn, S.D.11
Wahl, R.L.12
-
44
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
-
2-s2.0-0345337254
-
McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998 16 8 2825 2833 2-s2.0-0345337254
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.8
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-López, A.J.2
Link, B.K.3
Levy, R.4
Czuczman, M.S.5
Williams, M.E.6
Heyman, M.R.7
Bence-Bruckler, I.8
White, C.A.9
Cabanillas, F.10
Jain, V.11
Ho, A.D.12
Lister, J.13
Wey, K.14
Shen, D.15
Dallaire, B.K.16
-
45
-
-
0032761164
-
+ B-cell non-Hodgkin's lymphoma
-
2-s2.0-0032761164
-
+ B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 1999 17 12 3793 3803 2-s2.0-0032761164
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.12
, pp. 3793-3803
-
-
Witzig, T.E.1
White, C.A.2
Wiseman, G.A.3
Gordon, L.I.4
Emmanouilides, C.5
Raubitschek, A.6
Janakiraman, N.7
Gutheil, J.8
Schilder, R.J.9
Spies, S.10
Silverman, D.H.S.11
Parker, E.12
Grillo-López, A.J.13
-
46
-
-
0842285646
-
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
-
2-s2.0-0842285646
-
Du Y., Honeychurch J., Cragg M. S., Bayne M., Glennie M. J., Johnson P. W. M., Illidge T. M., Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004 103 4 1485 1494 10.1182/blood-2003-06-2037 2-s2.0-0842285646
-
(2004)
Blood
, vol.103
, Issue.4
, pp. 1485-1494
-
-
Du, Y.1
Honeychurch, J.2
Cragg, M.S.3
Bayne, M.4
Glennie, M.J.5
Johnson, P.W.M.6
Illidge, T.M.7
-
47
-
-
42049087214
-
In vitro evaluation of radioprotective and radiosensitizing effects of rituximab
-
2-s2.0-42049087214
-
Kapadia N. S., Engles J. M., Wahl R. L., In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. The Journal of Nuclear Medicine 2008 49 4 674 678 10.2967/jnumed.107.043752 2-s2.0-42049087214
-
(2008)
The Journal of Nuclear Medicine
, vol.49
, Issue.4
, pp. 674-678
-
-
Kapadia, N.S.1
Engles, J.M.2
Wahl, R.L.3
-
48
-
-
50949166628
-
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
-
2-s2.0-50949166628
-
Ivanov A., Krysov S., Cragg M. S., Illidge T., Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clinical Cancer Research 2008 14 15 4925 4934 10.1158/1078-0432.CCR-07-5072 2-s2.0-50949166628
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.15
, pp. 4925-4934
-
-
Ivanov, A.1
Krysov, S.2
Cragg, M.S.3
Illidge, T.4
-
49
-
-
0029835449
-
131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer
-
2-s2.0-0029835449
-
131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clinical Cancer Research 1996 2 11 1811 1818 2-s2.0-0029835449
-
(1996)
Clinical Cancer Research
, vol.2
, Issue.11
, pp. 1811-1818
-
-
Meredith, R.F.1
Khazaeli, M.B.2
Plott, W.E.3
Grizzle, W.E.4
Liu, T.5
Schlom, J.6
Russell, C.D.7
Wheeler, R.H.8
Lobuglio, A.F.9
-
50
-
-
67650360760
-
131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas
-
2-s2.0-67650360760
-
131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clinical Cancer Research 2009 15 13 4484 4492 10.1158/1078-0432.CCR-09-0035 2-s2.0-67650360760
-
(2009)
Clinical Cancer Research
, vol.15
, Issue.13
, pp. 4484-4492
-
-
Meyer, T.1
Gaya, A.M.2
Dancey, G.3
Stratford, M.R.L.4
Othman, S.5
Sharma, S.K.6
Wellsted, D.7
Taylor, N.J.8
Stirling, J.J.9
Poupard, L.10
Folkes, L.K.11
Chan, P.12
Pedley, R.B.13
Chester, K.A.14
Owen, K.15
Violet, J.A.16
Malaroda, A.17
Green, A.J.18
Buscombe, J.19
Padhani, A.R.20
Rustin, G.J.21
Begent, R.H.22
more..
-
51
-
-
85047684300
-
Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
-
2-s2.0-77950949514
-
Kraeber-Bodéré F., Bodet-Milin C., Niaudet C., Saï-Maurel C., Moreau A., Faivre-Chauvet A., Thomare P., Deleris G., Estieu-Gionnet K., Bikfalvi A., Barbet J., Paris F., Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. The Journal of Nuclear Medicine 2010 51 4 624 631 10.22967/jnumed.109.070714 2-s2.0-77950949514
-
(2010)
The Journal of Nuclear Medicine
, vol.51
, Issue.4
, pp. 624-631
-
-
Kraeber-Bodéré, F.1
Bodet-Milin, C.2
Niaudet, C.3
Saï-Maurel, C.4
Moreau, A.5
Faivre-Chauvet, A.6
Thomare, P.7
Deleris, G.8
Estieu-Gionnet, K.9
Bikfalvi, A.10
Barbet, J.11
Paris, F.12
-
52
-
-
76549177140
-
Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques
-
2-s2.0-76549177140
-
Gold P., Freedman S. O., Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine 1965 121 439 462 2-s2.0-76549177140
-
(1965)
The Journal of Experimental Medicine
, vol.121
, pp. 439-462
-
-
Gold, P.1
Freedman, S.O.2
-
53
-
-
0022858686
-
111In-labeled anticarcinoembryonic antigen monoclonal antibody
-
2-s2.0-0022858686
-
111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Research 1986 46 12 6494 6502 2-s2.0-0022858686
-
(1986)
Cancer Research
, vol.46
, Issue.12
, pp. 6494-6502
-
-
Beatty, J.D.1
Duda, R.B.2
Williams, L.E.3
Sheibani, K.4
Paxton, R.J.5
Philben, V.J.6
Werner, J.L.7
Shively, J.E.8
Vlahos, W.G.9
-
54
-
-
0347995052
-
90Y-anticarcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer
-
2-s2.0-0347995052
-
90Y-anticarcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clinical Cancer Research 2003 9 16 5842 5852 2-s2.0-0347995052
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.16
, pp. 5842-5852
-
-
Wong, J.Y.C.1
Shibata, S.2
Williams, L.E.3
Kwok, C.S.4
Liu, A.5
Chu, D.Z.6
Yamauchi, D.M.7
Wilczynski, S.8
Ikle, D.N.9
Wu, A.M.10
Yazaki, P.J.11
Shively, J.E.12
Doroshow, J.H.13
Raubitschek, A.A.14
-
55
-
-
33744816826
-
90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies
-
2-s2.0-33744816826
-
90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biotherapy and Radiopharmaceuticals 2006 21 2 88 100 10.1089/cbr.2006.21.88 2-s2.0-33744816826
-
(2006)
Cancer Biotherapy and Radiopharmaceuticals
, vol.21
, Issue.2
, pp. 88-100
-
-
Wong, J.Y.C.1
Chu, D.Z.2
Williams, L.E.3
Liu, A.4
Zhan, J.5
Yamauchi, D.M.6
Wilczynski, S.7
Wu, A.M.8
Yazaki, P.J.9
Shively, J.E.10
Leong, L.11
Raubitschek, A.A.12
-
56
-
-
0030952706
-
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti- carcinoembryonic antigen murine monoclonal antibody IgG
-
2-s2.0-0030952706
-
Behr T. M., Sharkey R. M., Juweid M. E., Dunn R. M., Vagg R. C., Ying Z., Zhang C., Swayne L. C., Vardi Y., Siegel J. A., Goldenberg D. M., Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti- carcinoembryonic antigen murine monoclonal antibody IgG. The Journal of Nuclear Medicine 1997 38 6 858 870 2-s2.0-0030952706
-
(1997)
The Journal of Nuclear Medicine
, vol.38
, Issue.6
, pp. 858-870
-
-
Behr, T.M.1
Sharkey, R.M.2
Juweid, M.E.3
Dunn, R.M.4
Vagg, R.C.5
Ying, Z.6
Zhang, C.7
Swayne, L.C.8
Vardi, Y.9
Siegel, J.A.10
Goldenberg, D.M.11
-
57
-
-
0029779766
-
2
-
2-s2.0-0029779766
-
2 The Journal of Nuclear Medicine 1996 37 9 1504 1510 2-s2.0-0029779766
-
(1996)
The Journal of Nuclear Medicine
, vol.37
, Issue.9
, pp. 1504-1510
-
-
Juweid, M.E.1
Sharkey, R.M.2
Behr, T.3
Swayne, L.C.4
Dunn, R.5
Siegel, J.6
Goldenberg, D.M.7
-
58
-
-
50349086793
-
2 after resection of liver metastases from colorectal cancer
-
2-s2.0-50349086793
-
2 after resection of liver metastases from colorectal cancer. Clinical Cancer Research 2008 14 11 3487 3493 10.1158/1078-0432.CCR-07-4698 2-s2.0-50349086793
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.11
, pp. 3487-3493
-
-
Ychou, M.1
Azria, D.2
Menkarios, C.3
Faurous, P.4
Quenet, F.5
Saint-Aubert, B.6
Rouanet, P.7
Pélegrin, M.8
Bascoul-Mollevi, C.9
Guerreau, D.10
Saccavini, J.11
Mach, J.12
Artus, J.13
Pèlegrin, A.14
-
59
-
-
8944222567
-
Phase i trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics
-
2-s2.0-8944222567
-
Yu B., Carrasquillo J., Milenic D., Chung Y., Perentesis P., Feuerestein I., Eggensperger D., Qi C. F., Paik C., Reynolds J., Grem J., Curt G., Siler K., Schlom J., Allegra C., Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. Journal of Clinical Oncology 1996 14 6 1798 1809 2-s2.0-8944222567
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.6
, pp. 1798-1809
-
-
Yu, B.1
Carrasquillo, J.2
Milenic, D.3
Chung, Y.4
Perentesis, P.5
Feuerestein, I.6
Eggensperger, D.7
Qi, C.F.8
Paik, C.9
Reynolds, J.10
Grem, J.11
Curt, G.12
Siler, K.13
Schlom, J.14
Allegra, C.15
-
60
-
-
0026634188
-
Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of Phase i trials
-
2-s2.0-0026634188
-
Breitz H. B., Weiden P. L., Vanderheyden J.-L., Appelbaum J. W., Bjorn M. J., Fer M. F., Wolf S. B., Ratliff B. A., Seiler C. A., Foisie D. C., Fisher D. R., Schroff R. W., Fritzberg A. R., Abrams P. G., Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of Phase I trials. The Journal of Nuclear Medicine 1992 33 6 1099 1112 2-s2.0-0026634188
-
(1992)
The Journal of Nuclear Medicine
, vol.33
, Issue.6
, pp. 1099-1112
-
-
Breitz, H.B.1
Weiden, P.L.2
Vanderheyden, J.-L.3
Appelbaum, J.W.4
Bjorn, M.J.5
Fer, M.F.6
Wolf, S.B.7
Ratliff, B.A.8
Seiler, C.A.9
Foisie, D.C.10
Fisher, D.R.11
Schroff, R.W.12
Fritzberg, A.R.13
Abrams, P.G.14
-
61
-
-
0029832918
-
Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy
-
2-s2.0-0029832918
-
Garin-Chesa P., Sakamoto J., Welt S., Real F. X., Rettig W. J., Old L. J., Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. International Journal of Oncology 1996 9 3 465 471 2-s2.0-0029832918
-
(1996)
International Journal of Oncology
, vol.9
, Issue.3
, pp. 465-471
-
-
Garin-Chesa, P.1
Sakamoto, J.2
Welt, S.3
Real, F.X.4
Rettig, W.J.5
Old, L.J.6
-
63
-
-
27244458791
-
131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results
-
2-s2.0-27244458791
-
131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. Journal of Clinical Oncology 2005 23 27 6763 6770 10.1200/JCO.2005.18.622 2-s2.0-27244458791
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.27
, pp. 6763-6770
-
-
Liersch, T.1
Meller, J.2
Kulle, B.3
Behr, T.M.4
Markus, P.5
Langer, C.6
Ghadimi, B.M.7
Wegener, W.A.8
Kovacs, J.9
Horak, I.D.10
Becker, H.11
Goldenberg, D.M.12
-
64
-
-
34548553392
-
131I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group
-
131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Annals of Surgical Oncology 2007 14 9 2577 2590 10.1245/s10434-006-9328-x 2-s2.0-34548553392
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.9
, pp. 2577-2590
-
-
Liersch, T.1
Meller, J.2
Bittrich, M.3
Kulle, B.4
Becker, H.5
Goldenberg, D.M.6
-
65
-
-
0026610881
-
Humanization of an anti-p185HER2 antibody for human cancer therapy
-
2-s2.0-0026610881
-
Carter P., Presta L., Gorman C. M., Ridgway J. B. B., Henner D., Wong W. L. T., Rowland A. M., Kotts C., Carver M. E., Shepard H. M., Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 1992 89 10 4285 4289 10.1073/pnas.89.10.4285 2-s2.0-0026610881
-
(1992)
Proceedings of the National Academy of Sciences of the United States of America
, vol.89
, Issue.10
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
Ridgway, J.B.B.4
Henner, D.5
Wong, W.L.T.6
Rowland, A.M.7
Kotts, C.8
Carver, M.E.9
Shepard, H.M.10
-
66
-
-
25444439808
-
Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol
-
2-s2.0-25444439808
-
Crow D. M., Williams L., Colcher D., Wong J. Y. C., Raubitschek A., Shively J. E., Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjugate Chemistry 2005 16 5 1117 1125 10.1021/bc0500948 2-s2.0-25444439808
-
(2005)
Bioconjugate Chemistry
, vol.16
, Issue.5
, pp. 1117-1125
-
-
Crow, D.M.1
Williams, L.2
Colcher, D.3
Wong, J.Y.C.4
Raubitschek, A.5
Shively, J.E.6
-
69
-
-
0028973292
-
90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase i trial
-
2-s2.0-0028973292
-
90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Research 1995 55 23 5921s 5924s 2-s2.0-0028973292
-
(1995)
Cancer Research
, vol.55
, Issue.23
, pp. 5921s-5924s
-
-
Schrier, D.M.1
Stemmer, S.M.2
Johnson, T.3
Kasliwal, R.4
Lear, J.5
Matthes, S.6
Taffs, S.7
Dufton, C.8
Glenn, S.D.9
Butchko, G.10
Ceriani, R.L.11
Rovira, D.12
Bunn, P.13
Shpall, E.J.14
Bearman, S.I.15
Purdy, M.16
Cagnoni, P.17
Jones, R.B.18
-
70
-
-
0000735189
-
Phase i study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer
-
Cagnoni P. J., Ceriani R. L., Cole W. C., Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. Cancer Biotherapy & Radiopharmaceuticals 1998 13 4 328
-
(1998)
Cancer Biotherapy & Radiopharmaceuticals
, vol.13
, Issue.4
, pp. 328
-
-
Cagnoni, P.J.1
Ceriani, R.L.2
Cole, W.C.3
-
71
-
-
0031281535
-
Initial immunochemical characterization of MX35 ovarian cancer antigen
-
2-s2.0-0031281535
-
Welshinger M., Yin B. W. T., Lloyd K. O., Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecologic Oncology 1997 67 2 188 192 10.1006/gyno.1997.4846 2-s2.0-0031281535
-
(1997)
Gynecologic Oncology
, vol.67
, Issue.2
, pp. 188-192
-
-
Welshinger, M.1
Yin, B.W.T.2
Lloyd, K.O.3
-
72
-
-
39449098149
-
Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas
-
article 3 2-s2.0-41749101537
-
Yin B. W. T., Kiyamova R., Chua R., Caballero O. L., Gout I., Gryshkova V., Bhaskaran N., Souchelnytskyi S., Hellman U., Filonenko V., Jungbluth A. A., Odunsi K., Lloyd K. O., Old L. J., Ritter G., Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immunity 2008 8 article 3 2-s2.0-41749101537
-
(2008)
Cancer Immunity
, vol.8
-
-
Yin, B.W.T.1
Kiyamova, R.2
Chua, R.3
Caballero, O.L.4
Gout, I.5
Gryshkova, V.6
Bhaskaran, N.7
Souchelnytskyi, S.8
Hellman, U.9
Filonenko, V.10
Jungbluth, A.A.11
Odunsi, K.12
Lloyd, K.O.13
Old, L.J.14
Ritter, G.15
-
73
-
-
67650088549
-
2: A Phase i Study
-
2-s2.0-67650088549
-
2: A Phase I Study. The Journal of Nuclear Medicine 2009 50 7 1153 1160 10.2967/jnumed.109.062604 2-s2.0-67650088549
-
(2009)
The Journal of Nuclear Medicine
, vol.50
, Issue.7
, pp. 1153-1160
-
-
Andersson, H.1
Cederkrantz, E.2
Bäck, T.3
Divgi, C.4
Elgqvist, J.5
Himmelman, J.6
Horvath, G.7
Jacobsson, L.8
Jensen, H.9
Lindegren, S.10
Palm, S.11
Hultborn, R.12
-
74
-
-
26444574248
-
Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer
-
2-s2.0-26444574248
-
DeNardo S. J., Richman C. M., Albrecht H., Burke P. A., Natarajan A., Yuan A., Gregg J. P., O'Donnell R. T., DeNardo G. L., Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clinical Cancer Research 2005 11 19 7187s 7194s 10.1158/1078-0432.CCR-1004-0013 2-s2.0-26444574248
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.19
, pp. 7187s-7194s
-
-
Denardo, S.J.1
Richman, C.M.2
Albrecht, H.3
Burke, P.A.4
Natarajan, A.5
Yuan, A.6
Gregg, J.P.7
O'Donnell, R.T.8
Denardo, G.L.9
-
75
-
-
0034895678
-
90Y-2IT-BAD-m170 for metastatic prostate cancer
-
2-s2.0-0034895678
-
90Y-2IT-BAD-m170 for metastatic prostate cancer. Clinical Cancer Research 2001 7 6 1561 1568 2-s2.0-0034895678
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.6
, pp. 1561-1568
-
-
O'Donnell, R.T.1
Denardo, S.J.2
Yuan, A.3
Shen, S.4
Richman, C.M.5
Lara, P.N.6
Griffith, I.J.7
Goldstein, D.S.8
Kukis, D.L.9
Martinez, G.S.10
Mirick, G.R.11
Denardo, G.L.12
Meyers, F.J.13
-
76
-
-
23844507146
-
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
-
2-s2.0-23844507146
-
Richman C. M., DeNardo S. J., O'Donnell R. T., Yuan A., Shen S., Goldstein D. S., Tuscano J. M., Wun T., Chew H. K., Lara P. N., Kukis D. L., Natarajan A., Meares C. F., Lamborn K. R., DeNardo G. L., High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clinical Cancer Research 2005 11 16 5920 5927 10.1158/1078-0432.CCR-05-0211 2-s2.0-23844507146
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5920-5927
-
-
Richman, C.M.1
Denardo, S.J.2
O'Donnell, R.T.3
Yuan, A.4
Shen, S.5
Goldstein, D.S.6
Tuscano, J.M.7
Wun, T.8
Chew, H.K.9
Lara, P.N.10
Kukis, D.L.11
Natarajan, A.12
Meares, C.F.13
Lamborn, K.R.14
Denardo, G.L.15
-
77
-
-
4344618391
-
Phase i trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
-
2-s2.0-4344618391
-
Milowsky M. I., Nanus D. M., Kostakoglu L., Vallabhajosula S., Goldsmith S. J., Bander N. H., Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of Clinical Oncology 2004 22 13 2522 2531 10.1200/JCO.2004.09.154 2-s2.0-4344618391
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.13
, pp. 2522-2531
-
-
Milowsky, M.I.1
Nanus, D.M.2
Kostakoglu, L.3
Vallabhajosula, S.4
Goldsmith, S.J.5
Bander, N.H.6
-
78
-
-
22044451179
-
177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
-
2-s2.0-22044451179
-
177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 2005 23 21 4591 4601 10.1200/JCO.2005.05.160 2-s2.0-22044451179
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.21
, pp. 4591-4601
-
-
Bander, N.H.1
Milowsky, M.I.2
Nanus, D.M.3
Kostakoglu, L.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
79
-
-
0034327512
-
213Bi]J591) for radioimmunotherapy of prostate cancer
-
2-s2.0-0034327512
-
213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Research 2000 60 21 6095 6100 2-s2.0-0034327512
-
(2000)
Cancer Research
, vol.60
, Issue.21
, pp. 6095-6100
-
-
McDevitt, M.R.1
Barendswaard, E.2
Ma, D.3
Lai, L.4
Curcio, M.J.5
Sgouros, G.6
Ballangrud, A.M.7
Finn, R.D.8
Pellegrini, V.9
Geerlings, M.W.10
Lee, M.11
Brechbiel, M.W.12
Bander, N.H.13
Cordon-Cardo, C.14
Scheinberg, D.A.15
-
80
-
-
0021800006
-
Antibodies against metal chelates
-
2-s2.0-0021800006
-
Reardan D. T., Meares C. F., Goodwin D. A., McTigue M., David G. S., Stone M. R., Leung J. P., Bartholomew R. M., Frincke J. M., Antibodies against metal chelates. Nature 1985 316 6025 265 268 10.1038/316265a0 2-s2.0-0021800006
-
(1985)
Nature
, vol.316
, Issue.6025
, pp. 265-268
-
-
Reardan, D.T.1
Meares, C.F.2
Goodwin, D.A.3
McTigue, M.4
David, G.S.5
Stone, M.R.6
Leung, J.P.7
Bartholomew, R.M.8
Frincke, J.M.9
-
81
-
-
0022469060
-
Monoclonal antibody hapten radiopharmaceutical delivery
-
2-s2.0-0022469060
-
Goodwin D. A., Mears C. F., McTigue M., David G. S., Monoclonal antibody hapten radiopharmaceutical delivery. Nuclear Medicine Communications 1986 7 8 569 580 10.1097/00006231-198608000-00002 2-s2.0-0022469060
-
(1986)
Nuclear Medicine Communications
, vol.7
, Issue.8
, pp. 569-580
-
-
Goodwin, D.A.1
Mears, C.F.2
McTigue, M.3
David, G.S.4
-
82
-
-
0023841413
-
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
-
2-s2.0-0023841413
-
Goodwin D. A., Meares C. F., McCall M. J., McTigue M., Chaovapong W., Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. The Journal of Nuclear Medicine 1988 29 2 226 234 2-s2.0-0023841413
-
(1988)
The Journal of Nuclear Medicine
, vol.29
, Issue.2
, pp. 226-234
-
-
Goodwin, D.A.1
Meares, C.F.2
McCall, M.J.3
McTigue, M.4
Chaovapong, W.5
-
83
-
-
33644869654
-
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
-
2-s2.0-33644869654
-
Goldenberg D. M., Sharkey R. M., Paganelli G., Barbet J., Chatal J., Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. Journal of Clinical Oncology 2006 24 5 823 834 10.1200/JCO.2005.03.8471 2-s2.0-33644869654
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.5
, pp. 823-834
-
-
Goldenberg, D.M.1
Sharkey, R.M.2
Paganelli, G.3
Barbet, J.4
Chatal, J.5
-
84
-
-
84881407469
-
A pretargeted PET imaging strategy based on bioorthogonal diels-alder click chemistry
-
2-s2.0-84881407469
-
Zeglis B. M., Sevak K. K., Reiner T., Mohindra P., Carlin S. D., Zanzonico P., Weissleder R., Lewis J. S., A pretargeted PET imaging strategy based on bioorthogonal diels-alder click chemistry. The Journal of Nuclear Medicine 2013 54 8 1389 1396 10.2967/jnumed.112.115840 2-s2.0-84881407469
-
(2013)
The Journal of Nuclear Medicine
, vol.54
, Issue.8
, pp. 1389-1396
-
-
Zeglis, B.M.1
Sevak, K.K.2
Reiner, T.3
Mohindra, P.4
Carlin, S.D.5
Zanzonico, P.6
Weissleder, R.7
Lewis, J.S.8
-
85
-
-
0023619395
-
Investigations of avidin and biotin for imaging applications
-
2-s2.0-0023619395
-
Hnatowich D. J., Virzi F., Rusckowski M., Investigations of avidin and biotin for imaging applications. The Journal of Nuclear Medicine 1987 28 8 1294 1302 2-s2.0-0023619395
-
(1987)
The Journal of Nuclear Medicine
, vol.28
, Issue.8
, pp. 1294-1302
-
-
Hnatowich, D.J.1
Virzi, F.2
Rusckowski, M.3
-
86
-
-
0033972577
-
90Y-DOTA-biotin
-
2-s2.0-0033972577
-
90Y-DOTA-biotin. The Journal of Nuclear Medicine 2000 41 1 131 140 2-s2.0-0033972577
-
(2000)
The Journal of Nuclear Medicine
, vol.41
, Issue.1
, pp. 131-140
-
-
Breitz, H.B.1
Weiden, P.L.2
Beaumier, P.L.3
Axworthy, D.B.4
Seiler, C.5
Su, F.6
Graves, S.7
Bryan, K.8
Reno, J.M.9
-
87
-
-
0033963824
-
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
-
2-s2.0-0033963824
-
Knox S. J., Goris M. L., Tempero M., Weiden P. L., Gentner L., Breitz H., Adams G. P., Axworthy D., Gaffigan S., Bryan K., Fisher D. R., Colcher D., Horak I. D., Weiner L. M., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical Cancer Research 2000 6 2 406 414 2-s2.0-0033963824
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.2
, pp. 406-414
-
-
Knox, S.J.1
Goris, M.L.2
Tempero, M.3
Weiden, P.L.4
Gentner, L.5
Breitz, H.6
Adams, G.P.7
Axworthy, D.8
Gaffigan, S.9
Bryan, K.10
Fisher, D.R.11
Colcher, D.12
Horak, I.D.13
Weiner, L.M.14
-
88
-
-
0034541209
-
A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy
-
2-s2.0-0034541209
-
Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., Axworthy D., A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Research 2000 60 23 6663 6669 2-s2.0-0034541209
-
(2000)
Cancer Research
, vol.60
, Issue.23
, pp. 6663-6669
-
-
Schultz, J.1
Lin, Y.2
Sanderson, J.3
Zuo, Y.4
Stone, D.5
Mallett, R.6
Wilbert, S.7
Axworthy, D.8
-
89
-
-
0037569482
-
Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?
-
2-s2.0-0037569482
-
Paganelli G., Chinol M., Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? European Journal of Nuclear Medicine and Molecular Imaging 2003 30 5 773 776 2-s2.0-0037569482
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.5
, pp. 773-776
-
-
Paganelli, G.1
Chinol, M.2
-
90
-
-
0141996882
-
Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?
-
2-s2.0-0141996882
-
Goldenberg D. M., Chang C. H., Sharkey R. M., Rossi E. A., Karacay H., McBride W., Hansen H. J., Chatal J., Barbet J., Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? European Journal of Nuclear Medicine and Molecular Imaging 2003 30 5 777 780 2-s2.0-0141996882
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.5
, pp. 777-780
-
-
Goldenberg, D.M.1
Chang, C.H.2
Sharkey, R.M.3
Rossi, E.A.4
Karacay, H.5
McBride, W.6
Hansen, H.J.7
Chatal, J.8
Barbet, J.9
-
91
-
-
0031193372
-
Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy
-
Janevik-Ivanovska E., Gautherot E., Hillairet de Boisferon M., Cohen M., Milhaud G., Tartar A., Rostene W., Barbet J., Gruaz-Guyon A., Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjugate Chemistry 1997 8 4 526 533 10.1021/bc970083h 2-s2.0-0031193372
-
(1997)
Bioconjugate Chemistry
, vol.8
, Issue.4
, pp. 526-533
-
-
Janevik-Ivanovska, E.1
Gautherot, E.2
Hillairet De Boisferon, M.3
Cohen, M.4
Milhaud, G.5
Tartar, A.6
Rostene, W.7
Barbet, J.8
Gruaz-Guyon, A.9
-
92
-
-
33646477258
-
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
-
2-s2.0-33646477258
-
Rossi E. A., Goldenberg D. M., Cardillo T. M., McBride W. J., Sharkey R. M., Chang C., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 6841 6846 10.1073/pnas.0600982103 2-s2.0-33646477258
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.18
, pp. 6841-6846
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Cardillo, T.M.3
McBride, W.J.4
Sharkey, R.M.5
Chang, C.6
-
93
-
-
0024395317
-
In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate
-
2-s2.0-0024395317
-
le Doussal J.-M., Martin M., Gautherot E., Delaage M., Barbet J., In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. The Journal of Nuclear Medicine 1989 30 8 1358 1366 2-s2.0-0024395317
-
(1989)
The Journal of Nuclear Medicine
, vol.30
, Issue.8
, pp. 1358-1366
-
-
Le Doussal, J.-M.1
Martin, M.2
Gautherot, E.3
Delaage, M.4
Barbet, J.5
-
94
-
-
0026591892
-
Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake
-
2-s2.0-0026591892
-
Goodwin D. A., Meares C. F., McTigue M., Chaovapong W., Diamanti C. I., Ransone C. H., McCall M. J., Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. The Journal of Nuclear Medicine 1992 33 11 2006 2013 2-s2.0-0026591892
-
(1992)
The Journal of Nuclear Medicine
, vol.33
, Issue.11
, pp. 2006-2013
-
-
Goodwin, D.A.1
Meares, C.F.2
McTigue, M.3
Chaovapong, W.4
Diamanti, C.I.5
Ransone, C.H.6
McCall, M.J.7
-
95
-
-
0033199028
-
Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate
-
2-s2.0-0033199028
-
Boerman O. C., Kranenborg M. H. G. C., Oosterwijk E., Griffiths G. L., McBride W. J., Oyen W. J. G., De Weijert M., Oosterwijk-Wakka J., Hansen H. J., Corstens F. H. M., Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Research 1999 59 17 4400 4405 2-s2.0-0033199028
-
(1999)
Cancer Research
, vol.59
, Issue.17
, pp. 4400-4405
-
-
Boerman, O.C.1
Kranenborg, M.H.G.C.2
Oosterwijk, E.3
Griffiths, G.L.4
McBride, W.J.5
Oyen, W.J.G.6
De Weijert, M.7
Oosterwijk-Wakka, J.8
Hansen, H.J.9
Corstens, F.H.M.10
-
96
-
-
27744440557
-
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft
-
2-s2.0-27744440557
-
Karacay H., Brard P., Sharkey R. M., Chang C., Rossi E. A., McBride W. J., Ragland D. R., Horak I. D., Goldenberg D. M., Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clinical Cancer Research 2005 11 21 7879 7885 10.1158/1078-0432.CCR-05-1246 2-s2.0-27744440557
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.21
, pp. 7879-7885
-
-
Karacay, H.1
Brard, P.2
Sharkey, R.M.3
Chang, C.4
Rossi, E.A.5
McBride, W.J.6
Ragland, D.R.7
Horak, I.D.8
Goldenberg, D.M.9
-
97
-
-
30744455270
-
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
-
2-s2.0-30744455270
-
Sharkey R. M., Cardillo T. M., Rossi E. A., Chang C., Karacay H., McBride W. J., Hansen H. J., Horak I. D., Goldenberg D. M., Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Medicine 2005 11 11 1250 1255 10.1038/nm1322 2-s2.0-30744455270
-
(2005)
Nature Medicine
, vol.11
, Issue.11
, pp. 1250-1255
-
-
Sharkey, R.M.1
Cardillo, T.M.2
Rossi, E.A.3
Chang, C.4
Karacay, H.5
McBride, W.J.6
Hansen, H.J.7
Horak, I.D.8
Goldenberg, D.M.9
-
98
-
-
33748375584
-
188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue
-
2-s2.0-33748375584
-
188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clinical Cancer Research 2006 12 16 4958 4964 10.1158/1078-0432.CCR-06-0844 2-s2.0-33748375584
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.16
, pp. 4958-4964
-
-
Liu, G.1
Dou, S.2
Mardirossian, G.3
He, J.4
Zhang, S.5
Liu, X.6
Rusckowski, M.7
Hnatowich, D.J.8
-
99
-
-
38349159550
-
Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF
-
Liu G., Dou S., Pretorius P. H., Liu X., Rusckowski M., Hnatowich D. J., Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 2 272 280 10.1007/s00259-007-0606-z 2-s2.0-38349159550
-
(2008)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.35
, Issue.2
, pp. 272-280
-
-
Liu, G.1
Dou, S.2
Pretorius, P.H.3
Liu, X.4
Rusckowski, M.5
Hnatowich, D.J.6
-
100
-
-
62449328137
-
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma
-
2-s2.0-62449328137
-
Sharkey R. M., Karacay H., Johnson C. R., Litwin S., Rossi E. A., Mebride W. J., Chang C., Goldenberg D. M., Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. The Journal of Nuclear Medicine 2009 50 3 444 453 10.2967/jnumed.108.058602 2-s2.0-62449328137
-
(2009)
The Journal of Nuclear Medicine
, vol.50
, Issue.3
, pp. 444-453
-
-
Sharkey, R.M.1
Karacay, H.2
Johnson, C.R.3
Litwin, S.4
Rossi, E.A.5
Mebride, W.J.6
Chang, C.7
Goldenberg, D.M.8
-
101
-
-
48549083845
-
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
-
2-s2.0-48549083845
-
Sharkey R. M., Karacay H., Litwin S., Rossi E. A., McBride W. J., Chang C., Goldenberg D. M., Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Research 2008 68 13 5282 5290 10.1158/0008-5472.CAN-08-0037 2-s2.0-48549083845
-
(2008)
Cancer Research
, vol.68
, Issue.13
, pp. 5282-5290
-
-
Sharkey, R.M.1
Karacay, H.2
Litwin, S.3
Rossi, E.A.4
McBride, W.J.5
Chang, C.6
Goldenberg, D.M.7
-
102
-
-
34848873532
-
Pretargeted radioimmunotherapy for B-cell lymphomas
-
2-s2.0-34848873532
-
Green D. J., Pagel J. M., Pantelias A., Hedin N., Lin Y., Wilbur D. S., Gopal A., Hamlin D. K., Press O. W., Pretargeted radioimmunotherapy for B-cell lymphomas. Clinical Cancer Research 2007 13 18 5598s 5603s 10.1158/1078-0432.CCR-07-1223 2-s2.0-34848873532
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.18
, pp. 5598s-5603s
-
-
Green, D.J.1
Pagel, J.M.2
Pantelias, A.3
Hedin, N.4
Lin, Y.5
Wilbur, D.S.6
Gopal, A.7
Hamlin, D.K.8
Press, O.W.9
-
103
-
-
66549084591
-
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
-
2-s2.0-66549084591
-
Pagel J. M., Orgun N., Hamlin D. K., Wilbur D. S., Gooley T. A., Gopal A. K., Park S. I., Green D. J., Lin Y., Press O. W., A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009 113 20 4903 4913 10.1182/blood-2008-11-187401 2-s2.0-66549084591
-
(2009)
Blood
, vol.113
, Issue.20
, pp. 4903-4913
-
-
Pagel, J.M.1
Orgun, N.2
Hamlin, D.K.3
Wilbur, D.S.4
Gooley, T.A.5
Gopal, A.K.6
Park, S.I.7
Green, D.J.8
Lin, Y.9
Press, O.W.10
-
104
-
-
19644371098
-
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies
-
2-s2.0-19644371098
-
Shen S., Forero A., LoBuglio A. F., Breitz H., Khazaeli M. B., Fisher D. R., Wang W., Meredith R. F., Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. The Journal of Nuclear Medicine 2005 46 4 642 651 2-s2.0-19644371098
-
(2005)
The Journal of Nuclear Medicine
, vol.46
, Issue.4
, pp. 642-651
-
-
Shen, S.1
Forero, A.2
Lobuglio, A.F.3
Breitz, H.4
Khazaeli, M.B.5
Fisher, D.R.6
Wang, W.7
Meredith, R.F.8
-
105
-
-
18244367701
-
Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
-
2-s2.0-18244367701
-
Grana C., Chinol M., Robertson C., Mazzetta C., Bartolomei M., De Cicco C., Fiorenza M., Gatti M., Caliceti P., Paganelli G., Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: a pilot study. British Journal of Cancer 2002 86 2 207 212 10.1038/sj.bjc.6600047 2-s2.0-18244367701
-
(2002)
British Journal of Cancer
, vol.86
, Issue.2
, pp. 207-212
-
-
Grana, C.1
Chinol, M.2
Robertson, C.3
Mazzetta, C.4
Bartolomei, M.5
De Cicco, C.6
Fiorenza, M.7
Gatti, M.8
Caliceti, P.9
Paganelli, G.10
-
106
-
-
0030731858
-
Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the 'adaptive response' and cannot be explained by a subpopulation of sensitive cells
-
2-s2.0-0030731858
-
Wouters B. G., Skarsgard L. D., Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the 'adaptive response' and cannot be explained by a subpopulation of sensitive cells. Radiation Research 1997 148 5 435 442 10.2307/3579320 2-s2.0-0030731858
-
(1997)
Radiation Research
, vol.148
, Issue.5
, pp. 435-442
-
-
Wouters, B.G.1
Skarsgard, L.D.2
-
107
-
-
35148881028
-
Drug resistance and the solid tumor microenvironment
-
2-s2.0-35148881028
-
Trédan O., Galmarini C. M., Patel K., Tannock I. F., Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 2007 99 19 1441 1454 10.1093/jnci/djm135 2-s2.0-35148881028
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.19
, pp. 1441-1454
-
-
Trédan, O.1
Galmarini, C.M.2
Patel, K.3
Tannock, I.F.4
-
108
-
-
0031909654
-
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
-
Overgaard J., Hansen H. S., Overgaard M., Bastholt L., Berthelsen A., Specht L., Lindeløv B., Jørgensen K., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology 1998 46 2 135 146 10.1016/S0167-8140(97)00220-X 2-s2.0-0031909654
-
(1998)
Radiotherapy and Oncology
, vol.46
, Issue.2
, pp. 135-146
-
-
Overgaard, J.1
Hansen, H.S.2
Overgaard, M.3
Bastholt, L.4
Berthelsen, A.5
Specht, L.6
Lindeløv, B.7
Jørgensen, K.8
|